Anteris Technologies (AVR) Barclays 27th Annual Global Healthcare Conference summary

Core strategy and market positioning

• Focused on the TAVR space for treating aortic stenosis, entering a $10B market dominated by two incumbents by 2028.

• Developed a new biomimetic, 3D-molded valve with superior clinical differentiation and hemodynamics, showing about 30% clinical superiority in trials with 100 patients.

• Targeting both market share and growth as the market expands, with strong physician interest in clinical data.

Product innovation and clinical benefits

• Introduced a biomimetic valve, not bioprosthetic, mimicking natural anatomy for better hemodynamics.

• Achieves mean gradients in the curative range (5-10 mmHg), previously unavailable to patients.

• Designed a balloon expandable platform based on physician input, addressing ease of use and adoption barriers.

• Combines the hemodynamic benefits of self-expanding valves with the preferred balloon expandable delivery.

Competitive landscape and differentiation

• Market is split 70%-30% between balloon expandable and self-expanding technologies, with clinicians favoring balloon expandable for ease and speed.

• Current leading products have trade-offs between delivery and hemodynamics; the new valve aims to offer both.

• Product offers superior hemodynamics on a balloon platform, especially beneficial for small annuli and valve-in-valve cases.